|
EIF5A expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.223790E-03 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.243360E-03 |
| Normal-vs-Stage2 |
3.739800E-03 |
| Normal-vs-Stage3 |
3.436300E-03 |
| Normal-vs-Stage4 |
6.949500E-02 |
| Stage1-vs-Stage2 |
5.387400E-01 |
| Stage1-vs-Stage3 |
8.495000E-01 |
| Stage1-vs-Stage4 |
2.351600E-01 |
| Stage2-vs-Stage3 |
5.168000E-01 |
| Stage2-vs-Stage4 |
1.588400E-01 |
| Stage3-vs-Stage4 |
3.573000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.164200E-04 |
| Normal-vs-AfricanAmerican |
1.155370E-01 |
| Normal-vs-Asian |
2.325700E-02 |
| Caucasian-vs-AfricanAmerican |
3.767600E-01 |
| Caucasian-vs-Asian |
5.941800E-01 |
| AfricanAmerican-vs-Asian |
6.580600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.958540E-03 |
| Normal-vs-Female |
1.820260E-03 |
| Male-vs-Female |
7.488000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.605800E-04 |
| Normal-vs-Age(41-60Yrs) |
8.483700E-03 |
| Normal-vs-Age(61-80Yrs) |
1.199520E-02 |
| Normal-vs-Age(81-100Yrs) |
2.848500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.536000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.595000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.813400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.408600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.074400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.783800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.017800E-01 |
| Classical-VS-Follicular |
1.408590E-01 |
| Classical-VS-Other |
7.908600E-01 |
| Classical-VS-Normal |
2.297600E-03 |
| Tall-VS-Follicular |
4.913400E-01 |
| Tall-VS-Other |
8.547000E-01 |
| Tall-VS-Normal |
1.243670E-02 |
| Follicular-VS-Other |
8.842600E-01 |
| Follicular-VS-Normal |
3.763900E-04 |
| Other-VS-Normal |
3.146600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.796000E-04 |
| Normal-vs-N1 |
3.250100E-02 |
| N0-vs-N1 |
4.800800E-01 |
|
|
